CMTs EXCLUSIVE Interviews and Podcasts

(Watch, Part 1) CEO, Jo Bhakdi and The Quantgene Story

Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.

By Michael Tetreault, Editor-in-Chief, Concierge Medicine Today/The DPC Journal and Host, The DocPreneur Leadership Broadcast/Podcast

Today our guest is Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.‍

Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.

Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.

 


Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.

LEARN MORE at https://www.quantgene.com

The Quantgene Story
We envision a future of medicine where all disease is prevented and detected at the earliest stage.

Quantgene unlocks the Deep Human Genome by building and deploying the world’s leading Deep Genomics solution. Our mission is to save lives through early detection, better prevention and more effective cures for all disease, starting with cancer.

Quantgene started in 2015 in a small UC Berkeley Lab under the leadership of Jo Bhakdi and Dr. Monika Hagen. Our theory was that most disease can be detected far earlier than today by introducing quantitative science and a new level of precision into medical practice. Since then, our team has spent over 4 years building the industry’s best team of pioneers and developing the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cell-free DNA (cfDNA) fragments with unprecedented depth and precision. In 2016, Quantgene launched its first clinical feasibility trial which continues today with the goal of adding 10,000 patient samples to the GRIFFIN platform by 2020.

We are determined to build a future where everyone is protected against most diseases through early detection with our innovative technology.

LEARN MORE at https://www.quantgene.com